Skip to content
Back Home
  • Home
  • About Us
    • Our History
    • Our Science
    • Our Partners
  • Scientific Platforms
    • ADCs
    • Publications
  • Team
  • News
  • Contact
Back Home
  • Search
  • Home
  • About Us
    • Our History
    • Our Science
    • Our Partners
  • Scientific Platforms
    • ADCs
    • Publications
  • Team
  • News
  • Contact
Home » Uncategorized » Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health
Uncategorized

Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health

by Mbio2018|Published September 1, 2018

https://projectreporter.nih.gov/project_info_description.cfm?aid=9623199&icde=51409496&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC&pball=

Project Number: 1R43CA228746-01A1

Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER

You may also like

Published January 30, 2025

Manhattan BioSolutions Initiates NCI PIVOT Collaboration in Pediatric Cancers

Published July 1, 2018

Manhattan BioSolutions has won prestigious Johnson & Johnson Innovation QuickFire Challenge Competition and award to receive free laboratory and office space at the newly open JLabs@NYC incubator in downtown Manhattan

https://jlabs.jnjinnovation.com/quickfire-challenges/jlabs-nyc-quickfire-challenge#paragraph-5131 https://www.prnewswire.com/news-releases/johnson–johnson-innovation-opens-jlabs–nyc-in-collaboration-with-new-york-state-and-the-new-york-genome-center-300670313.html

Published August 23, 2021

EVQLV and Manhattan BioSolutions Announce Grant Award from UB CAT

New York City, New York Jun 29, 2021 (Issuewire.com)  – EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, […]

Published August 12, 2022

Manhattan BioSolutions, Inc. Signs Commercial Evaluation License Agreements with the National Institutes of Health (NIH) for Use of Monoclonal Antibodies in Novel Antibody-Drug Conjugate (ADC) Oncology Programs

NEW YORK, NY / ACCESSWIRE / July 20, 2022 / Manhattan BioSolutions, Inc. today announced it has entered into two commercial evaluation license […]

Post navigation

  • Previous post Manhattan BioSolutions has won prestigious Johnson & Johnson Innovation QuickFire Challenge Competition and award to receive free laboratory and office space at the newly open JLabs@NYC incubator in downtown Manhattan
  • Back to post list
  • Next post Manhattan BioSolutions establishes new laboratory space at the JLabs JNJ Innovation incubator in New York City

© 2026 Manhattan BioSolutions – All rights reserved

Powered by WP – Designed with the Customizr theme